NO961536D0 - Preparat av bisfosfonater og veksthormonsekretagoga - Google Patents

Preparat av bisfosfonater og veksthormonsekretagoga

Info

Publication number
NO961536D0
NO961536D0 NO961536A NO961536A NO961536D0 NO 961536 D0 NO961536 D0 NO 961536D0 NO 961536 A NO961536 A NO 961536A NO 961536 A NO961536 A NO 961536A NO 961536 D0 NO961536 D0 NO 961536D0
Authority
NO
Norway
Prior art keywords
bisphosphonates
preparation
growth hormone
hormone secretagogue
secretagogue
Prior art date
Application number
NO961536A
Other languages
English (en)
Other versions
NO961536L (no
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO961536D0 publication Critical patent/NO961536D0/no
Publication of NO961536L publication Critical patent/NO961536L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO961536A 1993-10-19 1996-04-18 Preparat av bisfosfonater og veksthormonsekretagoga NO961536L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO961536D0 true NO961536D0 (no) 1996-04-18
NO961536L NO961536L (no) 1996-06-18

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961536A NO961536L (no) 1993-10-19 1996-04-18 Preparat av bisfosfonater og veksthormonsekretagoga

Country Status (16)

Country Link
EP (1) EP0813414A4 (no)
JP (1) JPH09504525A (no)
KR (1) KR960705575A (no)
CN (1) CN1136278A (no)
AU (1) AU8083694A (no)
BG (1) BG100517A (no)
BR (1) BR9407869A (no)
CA (1) CA2173333A1 (no)
CZ (1) CZ109196A3 (no)
FI (1) FI961681A (no)
HU (1) HUT75224A (no)
LV (1) LV11432B (no)
NO (1) NO961536L (no)
PL (1) PL314003A1 (no)
SK (1) SK49796A3 (no)
WO (1) WO1995011029A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ATE288444T1 (de) * 1995-05-29 2005-02-15 Pfizer Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
CA2234817A1 (en) * 1995-10-27 1997-05-01 Mandana Asgharnejad Wet granulation formulation of a growth hormone secretagogue
CA2240186A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AU3025997A (en) * 1996-05-31 1998-01-05 Novo Nordisk A/S Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
AU4993497A (en) * 1996-10-25 1998-05-22 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (ja) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド 成長ホルモン分泌促進物質関連受容体および核酸
JP2002522058A (ja) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド イヌ成長ホルモン分泌促進物質受容体
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
WO2000074685A1 (fr) * 1999-06-02 2000-12-14 Sumitomo Pharmaceuticals Co., Ltd. Preparations orales d'etidronate disodique
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
DK1372669T3 (da) * 2001-01-23 2005-10-17 Gador Sa Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2003220441A1 (en) 2002-04-09 2003-10-27 Eli Lilly And Company Dipeptidic growth hormone secretagogues
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
DK2266584T3 (da) * 2003-05-07 2013-01-02 Osteologix As Sammensætning med strontium og D-vitamin til profylakse og/eller behandling af brusk- og knogletilstande
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006023852A2 (en) 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
KR20080098070A (ko) 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
JP2009527568A (ja) 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
JP2009542670A (ja) 2006-06-29 2009-12-03 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (ja) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
MX2010003373A (es) 2007-10-03 2010-04-30 Vertex Pharma Moduladores de receptores muscarinicos.
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
SG11202112922WA (en) 2019-05-22 2021-12-30 Massachusetts Inst Technology Circular rna compositions and methods
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU568433B2 (en) * 1984-04-30 1987-12-24 Procter & Gamble Company, The Treating osteoporosis
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
CA2173333A1 (en) 1995-04-27
HUT75224A (en) 1997-04-28
AU8083694A (en) 1995-05-08
KR960705575A (ko) 1996-11-08
BG100517A (en) 1996-11-29
BR9407869A (pt) 1996-10-29
EP0813414A1 (en) 1997-12-29
FI961681A0 (fi) 1996-04-17
NO961536L (no) 1996-06-18
CN1136278A (zh) 1996-11-20
FI961681A (fi) 1996-06-12
JPH09504525A (ja) 1997-05-06
HU9601013D0 (en) 1996-06-28
PL314003A1 (en) 1996-08-05
SK49796A3 (en) 1997-05-07
EP0813414A4 (en) 1999-07-21
WO1995011029A1 (en) 1995-04-27
LV11432A (lv) 1996-08-20
CZ109196A3 (en) 1996-10-16
LV11432B (en) 1996-12-20

Similar Documents

Publication Publication Date Title
NO961536D0 (no) Preparat av bisfosfonater og veksthormonsekretagoga
NO962764D0 (no) Kilelös lås for orientering og forankring av brönnverktöy
DE69637063D1 (de) Oral verfügbare wachstumshormon-sekretagoge
DK93992D0 (da) Depotpraeparat og fremgangsmaade til fremstilling deraf
NO952294D0 (no) Spiropiperidiner og homologer aktiverer frigivelse av veksthormon
EP0503301A3 (en) Peptide derivatives and application thereof
CS135591A2 (en) Method of peptide preparation
PL291383A1 (en) Pesticide and method of obtaining same
NO932282D0 (no) Oljeaktig preparat og fremgangsmaate for fremstilling av dette
NO932912D0 (no) Preparat og fremgangsmaater til generering av ben
DK0512547T3 (da) Smertekontrollerende præparat og fremgangsmåde til fremstilling deraf
EP0536960A3 (en) Preparation of 2-hydroxymandelic acids and 2-hydroxybenzaldehydes
PL292307A1 (en) Insecticide and method of obtaining same
NO952261D0 (no) Antacidiumforbindelser og fremgangsmåte for fremstilling derav
DK106089A (da) Fremgangsmaade til fremstilling af alkansulfonylhalogenider og alkansulfonsyrer
EE9800147A (et) Kasvuhormooni sekretagoogi polümorfsed vormid
AU2447792A (en) Element and method of preparing this element
NO912783D0 (no) Fluoridforbindelse og fremstilling og anvendelse av denne.
SE9200678D0 (sv) Use of human growth hormone
GB9026254D0 (en) Peptide compound and its preparation
ZA913417B (en) Peptide compound and its preparation
GB9317341D0 (en) Peptide compound and process of preparation thereof
GB9222233D0 (en) Peptide compound and process of preparation@ thereof
PL290102A1 (en) Method of obtaining peptides
NO945021D0 (no) Sammensetninger for inhibisjon av proteinhormondannelse og anvendelse derav